
Atara Biotherapeutics Inc
NASDAQ:ATRA

Intrinsic Value
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which pioneers the development of transformative therapies for patients with serious diseases including solid tumors, hematol... [ Read More ]
The intrinsic value of one
ATRA
stock under the Base Case scenario is
-5.173
USD.
Compared to the current market price of 0.671 USD,
Atara Biotherapeutics Inc
is
Overvalued by 100%.

Valuation History
Atara Biotherapeutics Inc

Intrinsic Value History...
Our system is conducting in-depth analyses to map out the stock's valuation journey. Thank you for waiting.
Fundamental Analysis
Balance Sheet Decomposition
Atara Biotherapeutics Inc
Current Assets | 119m |
Cash & Short-Term Investments | 102m |
Receivables | 200k |
Other Current Assets | 16.1m |
Non-Current Assets | 70.1m |
PP&E | 63.8m |
Other Non-Current Assets | 6.3m |
Current Liabilities | 79.1m |
Accounts Payable | 6.5m |
Accrued Liabilities | 60.1m |
Other Current Liabilities | 12.5m |
Non-Current Liabilities | 161m |
Other Non-Current Liabilities | 161m |
ATRA Profitability Score
Profitability Due Diligence
Atara Biotherapeutics Inc's profitability score is 16/100. The higher the profitability score, the more profitable the company is.

Score
Atara Biotherapeutics Inc's profitability score is 16/100. The higher the profitability score, the more profitable the company is.
ATRA Solvency Score
Solvency Due Diligence
Atara Biotherapeutics Inc's solvency score is 35/100. The higher the solvency score, the more solvent the company is.

Score
Atara Biotherapeutics Inc's solvency score is 35/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ATRA Price Targets Summary
Atara Biotherapeutics Inc
According to Wall Street analysts, the average 1-year price target for
ATRA
is 4.019 USD
with a low forecast of 0.404 USD and a high forecast of 13.65 USD.
Ownership
ATRA Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
ATRA Price
Atara Biotherapeutics Inc
Average Annual Return | -16.14% |
Standard Deviation of Annual Returns | 29.89% |
Max Drawdown | -99% |
Market Capitalization | 68.4m USD |
Shares Outstanding | 101 100 000 |
Percentage of Shares Shorted | 8.21% |
Company Profile


Country
Industry
Market Cap
Dividend Yield
Description
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which pioneers the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. The company is headquartered in South San Francisco, California and currently employs 578 full-time employees. The company went IPO on 2014-10-16. The firm is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune disease. Its platform leverages the biology of EBV T cells and has the capability to treat a range of EBV-driven diseases or other serious diseases through engineered chimeric antigen receptors (CARs) or T-cell receptors (TCRs). The Company’s pipeline products include Tab-cel, ATA188, ATA2271, ATA3271 and ATA3219. The Company’s T-cell immunotherapy, tab-cel (tabelecleucel), is in Phase III development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases. Its ATA188 is a T-cell immunotherapy for the treatment of multiple sclerosis.